Cagrilintide and Semaglutide Peptide Profiles

Cagrilintide Profile
Cagrilintide is a synthetic long‑acting analogue of the hormone amylin, designed to mimic the natural pancreatic hormone co‑secreted with insulin that regulates appetite, gastric emptying, and glucose homeostasis. It acts as an amylin receptor agonist with affinity for amylin and calcitonin receptors in the hindbrain, enhancing satiety and slowing gastric emptying, which reduces food intake and supports weight loss. Cagrilintide is under clinical investigation (including phase III REDEFINE trials) both as monotherapy and as part of combination therapy with semaglutide for obesity and type 2 diabetes management. In clinical studies, once‑weekly cagrilintide has been associated with clinically meaningful weight reduction versus placebo, with dose‑dependent effects observed in overweight and obese populations. (Wikipedia)

Semaglutide Profile
Semaglutide is a peptide analogue of glucagon‑like peptide‑1 (GLP‑1) that functions as a GLP‑1 receptor agonist. It enhances insulin secretion, inhibits glucagon release, slows gastric emptying, reduces appetite, and improves glycemic control. Semaglutide’s long half‑life supports once‑weekly subcutaneous dosing for chronic weight management and type 2 diabetes treatment. It is marketed under brand names including Ozempic, Wegovy, Rybelsus, and is one of the most prescribed metabolic drugs globally. Common side effects include gastrointestinal symptoms such as nausea and vomiting. (Wikipedia)

Combined Mechanism & Synergy
When combined (as CagriSema), cagrilintide’s satiety and gastric‑emptying effects complement semaglutide’s GLP‑1‑mediated appetite suppression and metabolic actions. Clinical trial data show that the fixed‑dose combination yields greater weight loss and improved glycemic outcomes compared with either agent alone in adults with overweight/obesity or type 2 diabetes. (American College of Cardiology)

Dosing Chart (Clinical/Investigational Context)
| Peptide | Typical Dose (Once‑Weekly) | Route | Primary Use | Comments |
| Cagrilintide | 2.4 mg | Subcutaneous | Weight management (investigational) | In phase III studies as weekly dose; appetite reduction via amylin pathway (ScienceDirect) |
| Semaglutide (Wegovy) | 2.4 mg | Subcutaneous | Chronic weight management | Standard approved dose for obesity; GLP‑1 receptor agonist (Wikipedia) |
| CagriSema (Combo) | 2.4 mg + 2.4 mg | Subcutaneous | Obesity / T2D (investigational/filing) | Fixed‑dose combination showing enhanced efficacy (Wikipedia) |

References (APA):
Cagrilintide. (n.d.). Wikipedia. https://en.wikipedia.org/wiki/Cagrilintide (Wikipedia)
Semaglutide. (n.d.). Wikipedia. https://en.wikipedia.org/wiki/Semaglutide (Wikipedia)
Cagrilintide/Semaglutide. (n.d.). Wikipedia. https://en.wikipedia.org/wiki/Cagrilintide/semaglutide (Wikipedia)
D’Ascanio, A. M., et al. (2024). A long‑acting amylin analog for the treatment of obesity. PubMed. (pubmed.ncbi.nlm.nih.gov)
REDEFINE trials of cagrilintide + semaglutide. (2025). NEJM. (American College of Cardiology)